Lumipulse® G pTau 181

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Tau phosphorylated at threonine 181 (pTau 181) in human cerebrospinal fluid (CSF).

This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

The CSF biomarker supports the probability of AD pathology only as an adjunct to other diagnostic evaluations.

      Contact sales for information
      Lumipulse® G pTau 181 Immunoreaction Cartridges

      Product number 230350

      3 x 14 Tests
      Lumipulse® G pTau 181 Calibrators set

      Product number 230367

      1 x 3 concentrations
      CE marked (IVDR)
      Please contact your local Fujirebio representative for the availability of this product in your country.
      Lumipulse G pTau 181 Immunoreaction Cartridges (230350) and Lumipulse G pTau 181 Calibrators set (230367) Lumipulse G CLIA analyzer cartridge close up LUMIPULSE G1200 fully automated CLEIA analyzer - cartridge loading

      Click here to navigate

      • Contact sales for information
      • Details
      • Conditions of sale
      • Citations
      • Documentation
      • Insights
      • Product inquiry
      • Related products
      • Webinars

      • Details

        See the LUMIPULSE G1200 working in this video:

         

      • Conditions of sale

        To read the end user conditions of sale for this product please visit our Resource center.

      • Citations

        The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

      • Insights

      • Product inquiry

        CAPTCHA

        The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

        For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

        If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

        • Review past webinars

        Neurodegenerative diseases
        Replay available
        2026/03/03 - 10:00 AM EST / 16:00 CET

        Mapping Synaptic Loss: Where β‑synuclein Fits in the Biomarker Landscape

        Watch replay
        Neurodegenerative diseases
        Replay available
        2025/11/19 - 10:00 AM EST / 16:00 CET

        Unlocking the biology of dementia with Lewy bodies: Biomarker insights from DDC to synapses

        Watch replay
        Neurodegenerative diseases
        Replay available
        2021/11/18 - 18 November 2021

        Preparing for the future of plasma based Alzheimers disease diagnostics

        Watch replay

      Veuillez confirmer que vous êtes un professionnel de la santé

      Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

      Choose your country or region

      Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
      The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.